INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
批准号:
6377170
负责人:
Arnold S. Freedman
金额:
$17.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-08-01 至 2002-07-31
关键词:
B lymphocyte apoptosis biological signal transduction bone marrow cell adhesion molecules cell cell interaction cell cycle cell differentiation cell growth regulation cell migration cell proliferation chemokine clinical research extracellular matrix fibronectins gene expression human tissue integrins ligands lymphocytic leukemia phosphorylation protein tyrosine kinase tissue /cell culture transfection
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In acute lymphoblastic leukemia (ALL), interactions of leukemic cells with bone marrow (BM) stroma is mediated by members of the beta1 integrin family on leukemic cells, and their respective ligands in the marrow environment, specifically VCAM-1 on the BM stromal cells and fibronectin in the extracellular matrix. In addition to serving adhesive functions, one of the ways by which integrins can transduce signals is through the activation of tyrosine kinases, and ultimately to downstream pathways which regulate specific gene expression, proliferation, and migration of cells. In a variety of cell types, integrin mediated signaling has been shown to be critical to regulation of normal and malignant cells growth and the control of apoptosis. Over the past several years we have studied beta1 integrin mediated signal transduction as it related to neoplastic pre-B cells. We have identified and focused on the major substrates, specifically a docking/adaptor protein, HEF1, which appears to be important in both oncogenic and cell adhesive signaling pathways. Moreover, HEF1 probably functions as an intermediary between tyrosine kinase dependent signal transduction pathways and cell cycle regulation through its interaction with molecules which are relevant to cell cycle control and cell differentiation. In this proposal, we plan to extend our studies of integrin signaling in ALL cells and how the molecules involved in the signaling pathways regulate cell growth and survival. To this end, we plan to undertake three specific aims. First, to investigate the role of HEF1 during integrin signaling in pre-B ALL cells. Second, to determine the consequences of modulating beta1 integrin signaling pathways on growth, survival, adhesion and migration of pre-B cell ALL cells. Third, we will examine the effect of the bone marrow stromal cell derived chemokine, SDF-1 on integrin signaling pathways and function. We hypothesize that the regulation of HEF1 phosphorylation in integrin signaling plays a central role to the regulation of ALL proliferation, survival, and migration. Understanding the cell-cell interaction between BM stromal cells and pre-B ALL cells may provide future therapeutic strategies with which to modulate the growth of these leukemias.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Integrins regulate survival of pre-B-ALL cells through differential IAP and caspase-7 ubiquitination and degradation.
整合素通过差异 IAP 和 caspase-7 泛素化和降解来调节前 B-ALL 细胞的存活。
DOI:
10.1038/sj.leu.2403298
发表时间:
2004
期刊:
Leukemia
影响因子:
11.4
作者:
[Astier,AL, Svoboda,M, Hinds,E, DeBeaumont,R, Munoz,O, Freedman,AS]
通讯作者:
Freedman,AS
CpG Plus Rituximab Therapy in Follicular Lymphoma
-
批准号:6792326
-
项目类别:
-
资助金额:$28.46万
-
财政年份:2004
-
负责人:Arnold S. Freedman
-
依托单位:
CpG Plus Rituximab Therapy in Follicular Lymphoma
-
批准号:6889316
-
项目类别:
-
资助金额:$28.27万
-
财政年份:2004
-
负责人:Arnold S. Freedman
-
依托单位:
Etanercept Therapy in Follicular Lymphoma
-
批准号:6585639
-
项目类别:
-
资助金额:$28.47万
-
财政年份:2002
-
负责人:Arnold S. Freedman
-
依托单位:
Etanercept Therapy in Follicular Lymphoma
-
批准号:6660312
-
项目类别:
-
资助金额:$28.46万
-
财政年份:2002
-
负责人:Arnold S. Freedman
-
依托单位:
TRANSLATIONAL THERAPEUTIC STRATEGIES FOR LOW GRADE LYMPHOMA
-
批准号:6314043
-
项目类别:
-
资助金额:$22.61万
-
财政年份:2000
-
负责人:Arnold S. Freedman
-
依托单位:
INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
-
批准号:6174196
-
项目类别:
-
资助金额:$16.65万
-
财政年份:1999
-
负责人:Arnold S. Freedman
-
依托单位:
INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
-
批准号:2841610
-
项目类别:
-
资助金额:$16.27万
-
财政年份:1999
-
负责人:Arnold S. Freedman
-
依托单位:
TRANSLATIONAL THERAPEUTIC STRATEGIES FOR LOW GRADE LYMPHOMA
-
批准号:6103050
-
项目类别:
-
资助金额:$22.61万
-
财政年份:1999
-
负责人:Arnold S. Freedman
-
依托单位:
TRANSLATIONAL THERAPEUTIC STRATEGIES FOR LOW GRADE LYMPHOMA
-
批准号:6269697
-
项目类别:
-
资助金额:$22.86万
-
财政年份:1998
-
负责人:Arnold S. Freedman
-
依托单位:
TRANSLATIONAL THERAPEUTIC STRATEGIES FOR LOW GRADE LYMPHOMA
-
批准号:6237543
-
项目类别:
-
资助金额:$22.11万
-
财政年份:1997
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER INTERACTIONS OF NORMAL/MALIGNANT B CELLS
-
批准号:2429747
-
项目类别:
-
资助金额:$17.75万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER ADHESION OF NORMAL/NEOPLASTIC B CELLS
-
批准号:2096409
-
项目类别:
-
资助金额:$19.09万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER INTERACTIONS OF NORMAL/MALIGNANT B CELLS
-
批准号:2096411
-
项目类别:
-
资助金额:$17.01万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER INTERACTIONS OF NORMAL/MALIGNANT B CELLS
-
批准号:2096413
-
项目类别:
-
资助金额:$17.4万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER ADHESION OF NORMAL/NEOPLASTIC B CELLS
-
批准号:3199670
-
项目类别:
-
资助金额:$18.42万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER INTERACTIONS OF NORMAL/MALIGNANT B CELLS
-
批准号:2712652
-
项目类别:
-
资助金额:$18.13万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER ADHESION OF NORMAL/NEOPLASTIC B CELLS
-
批准号:3199668
-
项目类别:
-
资助金额:$17.5万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
NCI PHYSICIAN-INVESTIGATOR DEVELOPMENT AWARD PROGRAM
-
批准号:3079608
-
项目类别:
-
资助金额:$6.33万
-
财政年份:1986
-
负责人:Arnold S. Freedman
-
依托单位:
NCI PHYSICIAN-INVESTIGATOR DEVELOPMENT AWARD PROGRAM
-
批准号:3079604
-
项目类别:
-
资助金额:$5.77万
-
财政年份:1986
-
负责人:Arnold S. Freedman
-
依托单位:
NCI PHYSICIAN-INVESTIGATOR DEVELOPMENT AWARD PROGRAM
-
批准号:3079607
-
项目类别:
-
资助金额:$6.05万
-
财政年份:1986
-
负责人:Arnold S. Freedman
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: